Advertisement

Topics

FDA says Clovis' Rubraca could be prostate cancer breakthrough

08:20 EDT 3 Oct 2018 | pharmaphorum

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has said that phase 2 data suggest the drug could represent ...

Original Article: FDA says Clovis' Rubraca could be prostate cancer breakthrough

NEXT ARTICLE

More From BioPortfolio on "FDA says Clovis' Rubraca could be prostate cancer breakthrough"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...